The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...
US regulators approved GSK Plc’s blood cancer drug, a decision that will allow the company to bring the medicine back to the ...
GSK tried again with the combination regimens, and two separate Phase 3 trials yielded promising results in 2024. In the ...
(Reuters) -The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in one ...
Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...
The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...
Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed ...
FDA approves GSK's Blenrep combo for relapsed multiple myeloma, showing 51% reduced death risk and tripled progression-free survival in Phase 3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback